Table 1.
FOXM1 expression by immunohistochemistry in poorly differentiated thyroid carcinoma (PDC) and anaplastic thyroid carcinoma (ATC)
|
Number of cases in each category (percentage of stained target cells) |
||||
|---|---|---|---|---|
| Sample diagnosis | Negative ( − ) | Low/weak (+) |
Medium/moderate (++) |
High/strong (+++) |
| Normal thyroid (13 cases) | 13 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
| PDC (78 cases-347 cores)a | 43 (55.1%) | 29 (37.2%) | 6 (7.7%) | 0 (0%) |
| ATC (41 cases-192 cores)a | 4 (9.7%) | 13 (31.7%) | 12 (29.3%) | 12 (29.3%) |
−, <5% of cells positive for nuclear FOXM1 expression; +, ≥5–≤25% of cells positive for nuclear FOXM1 expression; ++, >25–<50% of cells positive for nuclear FOXM1 expression; +++, ≥50% of cells positive for nuclear FOXM1 expression.
a
To improve the representativity of the expression analysis, two to six core biopsies of 1 mm in diameter, from different regions of the same specimen or different blocks of the same tumor, were included in the TMAs.